{"entity":{"id":"nct07093970","kind":"trial","name":"A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of MRG006A in advanced solid tumours, run by Lepu Biopharma Co., Ltd., now recruiting.","summary":"A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07093970 by Lepu Biopharma Co., Ltd., with 343 participants planned, started 2024-07-24 and due to reach its primary completion in 2027-12. Interventions recorded: MRG006A.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07093970","url":"https://clinicaltrials.gov/study/NCT07093970"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["lepu-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07093970","phase":"1/2","setting":"A Phase I/II, Open-label, Multi-center, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of MRG006A in Patients With Advanced Solid Tumors","sponsor":"Lepu Biopharma Co., Ltd.","enrolled":343,"outcomes":[]},"route":"/trials/nct07093970/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"lepu-biopharma","kind":"company","name":"Lepu Biopharma","route":"/companies/lepu-biopharma/"}]}}